- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00934817
Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg
An Open, Randomized, Two-Treatment, Crossover Study to Assess the Dose Proportionality of Glimepiride Between Amaryl M 1mg/500mg and 2mg/500mg (Glimepiride-Metformin Fixed Dose Combination Tablet) in Healthy Subjects
The pharmacokinetics of glimepiride and metformin HCl will be compared after single dose intake of both combinations in order to answer the following questions:
- Is Amaryl-M 1/500 mg (Test tablet) proportional to Amaryl-M 2/500 mg tablet with regard to the glimepiride component?
- Is Amaryl-M 1/500 mg (Test tablet) tolerable comparing with Amaryl-M 2/500 mg?
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
16 subjects were randomized to each of 2 sequence groups which have different treatment order of the study drug in each period.
Only healthy volunteers had screening tests such as medical inquiry, physical examination, clinical laboratory test, etc. within 4 weeks (-28d ~ -1d) prior to drug administration (1d) and those determined eligible for this study were selected and randomized between screening and 1 day prior to the first administration of study medication (-1d). Then, the subjects were admitted to the clinical research center of Seoul National University Hospital by 9 p.m. of -1d and then, they were not allowed to take anything except water.
After one week of washout period, subjects went on to the second phase of treatment period and were administered according to the treatment order in a crossover way. For the subjects who completed the study, post-study visit tests were performed after a designated time had passed.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age: Between 19 to 45 years of age, inclusive (age based on the date to give the informed consent)
- Ideal body weight (Broca index): between 50 to 90 kg, inclusive, and within ±20 % of Ideal Body Weight, [(Height in cm-100)×0.9]
- Subjects who are appropriate to participate in this study judged from clinical laboratory and physical examinations taken within 4weeks prior to the start of study
- Subjects who are able to abstain from caffeine or caffeine-containing products (e.g., coffee, cola, tea, chocolate), grapefruit and grapefruit containing products, alcohol and smoking within 7 days before dosing and during the hospitalization
- Subjects who give their informed consent voluntarily to participate in the study
Exclusion Criteria:
- History of allergies including drug allergy, except untreated, asymptomatic, seasonal allergies at the time of dosing
- Use any medication not considered acceptable by the clinical investigator during the last 10 days period before the start day of the study
- Use of any inducer or inhibitors of metabolizing enzymes during the last 28 days before the start day of the study.
- History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease
- History of a significant surgical resection of gastrointestinal tract except appendectomy
- Abnormal clinical laboratory findings, especially for AST or ALT > 1.25 fold, total bilirubin > 1.5 fold of upper normal level
- Pregnant or lactating woman or woman of childbearing potential without medically acceptable birth control during the study
- Evidence of alcohol abuse (defined as regular alcohol intake that exceeds 24 oz [675 ml] of beer, 12 oz [340 ml] of wine or 160 ml of soju or 3 oz [85 ml] hard liquor per day [e.g., brandy, whiskey, gin]) or drug abuse
- Heavy smokers (> 10 cigarettes per day), or can't quit smoking during hospitalization
- Participation in clinical trials of any drug within 3 months prior to the start of study
- Donation of 200ml of whole blood within 4 weeks or 400ml within 12 weeks prior to the start of study
- Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or HIV antibody
- Judged to be inappropriate for the study by the investigator
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: TR sequential group
Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
|
single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
Autres noms:
single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
Autres noms:
|
Comparateur actif: RT sequential group
Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
|
single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
Autres noms:
single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Plasma drug concentrations of glimepiride and metformin, PK parameters: AUCt, AUCinf, Cmax, Tmax, T1/2
Délai: pre-dose (= 1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 30 hrs after drug administration
|
pre-dose (= 1d 0h), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 30 hrs after drug administration
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Physical examination, clinical laboratory tests
Délai: Screening, 2 day, 9 day, 13-15 day
|
Screening, 2 day, 9 day, 13-15 day
|
Vital sign
Délai: screening, 1 day, 2 day, 8 day, 9 day, 13-15 day
|
screening, 1 day, 2 day, 8 day, 9 day, 13-15 day
|
Adverse event
Délai: 1 day, 2 day, 8 day, 9 day, 13-15 day
|
1 day, 2 day, 8 day, 9 day, 13-15 day
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: In-Jin Jang, Professor, Seoul National University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GLIME_L_02279
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur En bonne santé
-
AstraZenecaParexelComplété
Essais cliniques sur Amaryl-M 2/500 mg
-
Handok Inc.ComplétéEn bonne santéCorée, République de
-
Canadian Heart Research CentreGlaxoSmithKlineComplétéDiabète sucré de type 2Canada
-
Medical College of WisconsinRecrutementGlioblastomeÉtats-Unis
-
Centre Hospitalier Universitaire, AmiensMerck Serono International SAComplétéTrouble rénal associé au diabète sucré de type IIFrance
-
Janssen Research & Development, LLCComplété
-
Betta Pharmaceuticals Co., Ltd.Pas encore de recrutementCancer du poumon non à petites cellules, mutation sensible à l'EGFRChine
-
DS BiopharmaRésiliéLa dermatite atopiqueÉtats-Unis, L'Autriche, Allemagne, Lettonie, Pologne
-
Taipei Medical UniversityComplété
-
Boehringer IngelheimEli Lilly and CompanyComplété
-
SINA Health Education and Welfare TrustComplétéSyndrome des ovaires polykystiques | Gain de poids | HbA1cPakistan